|1.||de Alwis, Dinesh P: 5 articles (02/2013 - 10/2011)|
|2.||Ilaria, Robert: 4 articles (02/2013 - 11/2008)|
|3.||Ermisch, Sabine: 2 articles (02/2013 - 06/2012)|
|4.||Wagner, Margaret M: 2 articles (01/2013 - 11/2011)|
|5.||Ilaria, Robert L: 2 articles (11/2011 - 10/2011)|
|6.||Keohan, M L: 1 article (02/2013)|
|7.||Lopez-Pousa, Antonio: 1 article (02/2013)|
|8.||Miller, Mary Alice: 1 article (02/2013)|
|9.||Ryan, Christopher W: 1 article (02/2013)|
|10.||Agulnik, Mark: 1 article (02/2013)|
11/01/2008 - "LY573636, as shown before in solid tumors, is effective in hematopoietic cell lines as well. "
11/01/2008 - "This targeted effect makes LY573636 a candidate for combined therapy regimens in patients with advanced or resistant cancers. "
01/01/2013 - "A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors."
11/01/2011 - "A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors."
11/01/2008 - "We studied for the first time, the anti-tumor properties of LY573636 against a variety of human hematopoietic malignancies, including AML, B-ALL, large B-cell and mantle cell lymphoma cell lines. "
|2.||Sarcoma (Soft Tissue Sarcoma)
|3.||Melanoma (Melanoma, Malignant)
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|5.||Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)